Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    23727422 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in Chronic Kidney Disease (CKD) Patients
Condition: Chronic Kidney Disease
Interventions: Biological: HEPLISAV;   Biological: Engerix-B

Indicates status has not been verified in more than two years